24 Oct 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Samsung BioLogics and Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction.
Terms of the agreement, including financial terms and products that would be manufactured at the facilities, have not been disclosed yet.
"We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards," said Mr Tae-Han Kim, president and CEO, Samsung BioLogics.
Mr Kim also said, "This collaboration with the world's largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing."